CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives

SIMPLE SUMMARY: The recent addition of cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (palbociclib, ribociclib, abemaciclib) to endocrine therapy have remarkably improved the outcome of patients with HR+ advanced breast cancer. However, some points of reflections are still undiscussed. To answ...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberto, Michela, Astone, Antonio, Botticelli, Andrea, Carbognin, Luisa, Cassano, Alessandra, D’Auria, Giuliana, Fabbri, Agnese, Fabi, Alessandra, Gamucci, Teresa, Krasniqi, Eriseld, Minelli, Mauro, Orlandi, Armando, Pantano, Francesco, Paris, Ida, Pizzuti, Laura, Portarena, Ilaria, Salesi, Nello, Scagnoli, Simone, Scavina, Paola, Tonini, Giuseppe, Vici, Patrizia, Marchetti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830463/
https://www.ncbi.nlm.nih.gov/pubmed/33477469
http://dx.doi.org/10.3390/cancers13020332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830463/
https://www.ncbi.nlm.nih.gov/pubmed/33477469
http://dx.doi.org/10.3390/cancers13020332

Ejemplares similares